Isocitrate dehydrogenase is a critical enzyme in the citric acid cycle. Mutated forms of IDH produce high levels of the (R)-enantiomer of 2-hydroxyglutarate (R-2-HG) and can contribute to the growth of tumors. IDH1 catalyzes this reaction in the cytoplasm, while IDH2 catalyzes this reaction in mitochondria. Mutations of IDH2 are more common than IDH1 mutations, 8 to 19% compared to 7 to 14% respectively, in those affected with AML.<unk>  disrupts this cycle by decreasing total (R)-2-HG levels in the mitochondria.
Enasidenib
Ivosidenib
Dabrafenib
Brigatinib
Tucatinib
Selpercatinib
Fostamatinib
Lorlatinib